Clinical Guidelines for Gout Management

Overview of Gout

Gout is a prevalent condition characterized by joint inflammation caused by the crystallization of uric acid. This disorder typically arises from either excessive production or insufficient excretion of uric acid.

2017 Guidelines by the British Society for Rheumatology

In 2017, the British Society for Rheumatology released updated clinical guidelines aimed at supporting clinicians in managing gout within primary care settings. These evidence-based guidelines are designed to empower both doctors and allied health professionals in their approach to treatment.

Key Components of the Updated Guidelines

The updated guidelines include several important recommendations:

Patient Education

Patients should be informed that gout attacks need to be addressed promptly and that it is crucial to maintain urate-lowering therapy (ULT) even during flare-ups.

Joint Care Recommendations

Affected joints should be rested, elevated, and kept cool to alleviate discomfort during an attack.

First-Line Medications

The primary medications for managing acute attacks include non-steroidal anti-inflammatory drugs (NSAIDs) at a maximum dose of 500 mg, either twice or four times daily, and colchicine.

Corticosteroid Use

For patients unable to tolerate NSAIDs, a brief course of oral corticosteroids or a single intramuscular corticosteroid injection may be recommended.

Interleukin-1 Inhibitors

If patients do not respond to standard treatments, the use of interleukin-1 inhibitors should be considered.

Alternative Medications for Hypertension

For patients on thiazide or loop diuretics, alternative antihypertensive medications may be warranted.

Pathophysiology and Lifestyle Education

Clinicians should explain the pathophysiology of gout to patients and highlight the significance of lifestyle modifications in managing the condition.

Hydration Recommendations

Patients with gout who have a history of renal stones are advised to drink at least 2 liters of water daily.

Importance of Adherence to ULT

The necessity of adhering to prescribed urate-lowering therapies should be emphasized, even for asymptomatic patients.

First-Line ULT Medications

Allopurinol, a xanthine oxidase inhibitor, is recommended as the first-line choice for urate-lowering therapy. If allopurinol is not tolerated, febuxostat can be considered as an alternative.

Uricosuric Agents

For patients resistant to xanthine oxidase inhibitors, uricosuric agents such as probenecid may be used.

Colchicine for Prophylaxis

Colchicine can be administered as prophylaxis against acute gout attacks.

Conclusion

The comprehensive guidelines provided by the British Society for Rheumatology serve as a vital resource, enabling clinicians to manage gout effectively and efficiently.

Reference

Hui, M., et al. (2017). The British Society of Rheumatology guideline for the management of gout. Rheumatology. Doi:10.1093/rheumatology/kex156